Pawel Kacperek/iStock via Getty Images Tarsus Pharmaceuticals ( NASDAQ: TARS ) quickly rose 3.5% amid some takeover speculation. The company is believed to have attracted some takeover interest and two larger rivals are said to be circling it, according to traders, who cited a Betaville "uncooked" alert that was circulating on Tuesday.
Tarsus ( TARS ) short interest is 26%. More on Tarsus Pharmaceuticals Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment Tarsus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Tarsus Pharmaceuticals Historical earnings data for Tarsus Pharmaceuticals.
